tract

(redirected from gastrointestinal tract)
Also found in: Dictionary, Thesaurus, Medical, Financial, Acronyms, Encyclopedia, Wikipedia.
References in periodicals archive ?
Primary and metastatic diseases in malignant melanoma of the gastrointestinal tract.
Coverage of the Gastrointestinal Tract Cancer pipeline on the basis of route of administration and molecule type.
Gastrointestinal Tract Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 133 Gastrointestinal Tract Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 142 Gastrointestinal Tract Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 150 Gastrointestinal Tract Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 157 Gastrointestinal Tract Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc.
Introduction: The Gastrointestinal Tract as Barrier and as Absorptive and Metabolic Organ
The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside.
Elan's formulation of naproxen is designed to overcome the adverse effects of this compound on the gastrointestinal tract.
Chapters that discuss diseases of the gastrointestinal tract in detail.
Dynogen's preclinical studies have also shown that DDP733 is minimally absorbed by the cells lining the gastrointestinal tract and, as a result, more of the product candidate remains available at the desired local site of action.
The foreign body can be gently pushed into the stomach if the distal patency of the esophagus can be verified, if there is no suggestion that the esophageal wall has been penetrated (which may occur with many longstanding foreign bodies), and if features of the foreign body do not pose a hazard to the distal gastrointestinal tract.
Aufderheide explains that Trypanosoma cruzi, the parasite that causes Chagas' disease, attacks the nerves in the gastrointestinal tract.
NASDAQ: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced the initiation of the first of two global, pivotal, phase 3 clinical trials to evaluate the safety and efficacy of intravenous methylnaltrexone for the treatment of post-operative ileus (POI), a debilitating impairment of the gastrointestinal tract that occurs after surgery.
They can also appear in both sexes in the gastrointestinal tract and in the skin.